University of Oxford – Target Discovery Institute

The Institute investigates drug target discovery across various diseases drawing on the expertise of the research staff on the Campus, Medical Science Division and wider University capitalizing on existing strengths in genetics and genomic medicine, molecular and cell biology, structural biology, chemistry, pharmacology and medicine.  The TDI is generously supported by our core partners, the UK government (HEFCE) and Li Ka Shing, and several University of Oxford contributors including the  Nuffield Department of Medicine, Department of Oncology and CRUK, Ludwig Institute for Cancer Research and Cardiovascular Medicine and the BHF.


Show full profile

Principal Disease Indication(s)

Oncology, Cardiovascular, Neurodegeneration and Inflammation


Platform(s)

RNAi, pharmacologically targeted small compound libraries, drug repurposing, Small molecules diverse (50K), and fragments


Technology(ies):

HCI, HTS plate reader, rtPCR, HTFACS and NGS


Funding sources:

UK government (HEFCE) and Li Ka Shing

University of Oxford:

Nuffield Department of Medicine

Department of Oncology and CRUK

Ludwig Institute for Cancer Research

Cardiovascular Medicine and the BHF


Personnel:

50+


Number of Screens / year (any size):

20


Medicinal Chemistry Follow-up:

Yes


Contact Details

Daniel Ebner

Operational Cell Screening Officer

Phone: +44 (0)1865 612 923
www.tdi.ox.ac.uk

Contact Form

To contact us, please fill in the form below


Getting there

Address: Old Road Campus, Oxford, Oxford OX3, UK
X
- Enter Your Location -
- or -